Regorafenib (Shiyao) 40mg*28's | CSPC Ouyi China | GLT

Generic Information: Shiyao (China)

Shiyao (石药/瑞戈非尼) is the CSPC Ouyi brand of regorafenib, manufactured by CSPC Ouyi Pharmaceutical Co., Ltd., part of one of China's largest pharmaceutical groups. This pack contains 28 film-coated tablets of 40 mg. As a domestic Chinese regorafenib, it provides a licensed, more accessible option for patients whose advanced cancer requires later-line multi-kinase inhibition.

What Is Regorafenib (Shiyao) Used For?

Shiyao is used to treat three advanced cancers. It is indicated for metastatic colorectal cancer that has progressed after standard chemotherapy plus anti-VEGF and, where applicable, anti-EGFR therapy; for gastrointestinal stromal tumour resistant to imatinib and sunitinib; and for hepatocellular carcinoma that has progressed on sorafenib. It is a disease-control therapy given after earlier treatments have failed.

How Does Regorafenib Work?

Regorafenib inhibits multiple kinases central to tumour growth and angiogenesis, including the VEGF receptors 1, 2 and 3, TIE2, PDGFR-α and β, FGFR-1 and 2, KIT, RET, RAF-1 and BRAF. This dual effect — slowing cancer-cell division while blocking new blood-vessel formation — is what lets a single drug work against colorectal cancer, gastrointestinal stromal tumour and hepatocellular carcinoma.

Indications

The approved indications are advanced colorectal cancer after prior standard therapy, imatinib- and sunitinib-resistant gastrointestinal stromal tumour, and sorafenib-refractory hepatocellular carcinoma. Treatment must be supervised by an oncologist, with liver function and blood pressure evaluated before and during therapy.

Dosage

The standard dose is 160 mg, taken as four 40 mg tablets once daily with a low-fat meal, in 28-day cycles of 21 days on and 7 days off. A 28-tablet pack supplies seven days of the active-treatment phase. The oncologist may reduce the dose to 120 mg or 80 mg daily if hand-foot skin reaction, diarrhoea or liver enzyme elevations occur.

Side Effects

Common side effects include hand-foot skin reaction, diarrhoea, fatigue, hypertension, decreased appetite and mucositis. More serious adverse events can include liver injury, bleeding, gastrointestinal perforation and cardiac ischaemia. Regular checks of liver function, blood pressure and blood counts are recommended, and patients should promptly report skin peeling, persistent diarrhoea, dark stools or chest pain.

Storage

Store Shiyao tablets at room temperature, protected from moisture, in the original packaging and out of the reach of children. Do not use beyond the expiry date printed on the pack.

Why Choose Shiyao Through GLT?

Shiyao offers overseas patients a genuine CSPC-manufactured regorafenib from a leading Chinese pharmaceutical group, typically at a cost well below Western originator pricing. GLT sources from established domestic manufacturers and ships worldwide from a Hong Kong-licensed facility, providing a dependable supply for longer-term cancer therapy.

How to Order

To order Shiyao (regorafenib) from GLT, contact us on WhatsApp at +86 15234153837 or by email at [email protected]. We will confirm current availability, pricing and delivery to your country, and we ship from a Hong Kong-licensed facility.

FAQ

Is Shiyao the same as Stivarga? Yes — it contains the same regorafenib molecule, manufactured by CSPC Ouyi as a licensed Chinese product.

What is the treatment cycle? 160 mg daily for 21 days, followed by a 7-day break, repeated every 28 days.

Do I need a prescription? Yes, regorafenib is prescription-only and requires a valid oncologist's prescription.